drugset / Trial / NCT03867994
Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.
RandomizedParallel-groupSingle-blindPrevention
Summary
This prospective study is intended to evaluate if carvedilol has any potential protective effect over atorvastatin on the development of contrast-induced nephropathy (CIN) following cardiac catheterization in patients with moderate to high risk for CIN.
Timeline
- Start
- 2016-02-01
- Primary completion
- 2017-05-15
- Completion
- 2017-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 40 mg | — |
| Subject | Carvedilol | Other / unclassified | 12.5 mg | — |
Indications
No indication recorded.